Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR27 | Q9NS67 | 4/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | IDH1 | O75874 | 6/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754388 | 0.82 | NPC1 (0.53) | GPR27ALPLIDH1NAMPTALDH1A1 | |
| SCHEMBL25754386 | 0.81 | KDR (0.49) | GPR27ALPLIDH1NAMPTALDH1A1 | |
| SCHEMBL23846502 | 0.80 | TP53 (0.50) | TP53ALDH1A1MAPTGSK3AGSK3B | |
| SCHEMBL23846481 | 0.78 | GPR27 (0.54) | GPR27IDH1PTK2B | |
| SCHEMBL25754403 | 0.77 | IDH1 (0.52) | IDH1 | |
| SCHEMBL25754345 | 0.76 | IDH1 (0.55) | ALPLIDH1ALDH1A1MAPTAPOBEC3G | |
| SCHEMBL25754353 | 0.76 | ABL1 (0.56) | ALPLIDH1NAMPTALDH1A1MAPT | |
| SCHEMBL25754396 | 0.76 | IDH1 (0.52) | GPR27IDH1MAPT | |
| SCHEMBL25754412 | 0.74 | ITGA1 (0.47) | GPR27ALPLIDH1MAPTPTK2B | |
| SCHEMBL23846385 | 0.73 | IDH1 (0.51) | GPR27IDH1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | GPR27 3560/4885ALPL 3721/4885TP53 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.